Provention bio announces positive interim results from first-in-human study of coxsackievirus b vaccine candidate prv-101

Red bank, n.j., oct. 26, 2021 /prnewswire/ -- provention bio, inc. (nasdaq: prvb), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced positive interim results from provent (protocol for coxsackievirus vaccine in healthy volunteers), a first-in-human study of prv-101, a polyvalent inactivated coxsackievirus b (cvb) vaccine candidate targeting all five key cvb strains associated with type 1 diabetes (t1d) autoimmunity.
PRVB Ratings Summary
PRVB Quant Ranking